Foundry Partners, LLC Ligand Pharmaceuticals Inc Transaction History

Foundry Partners, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 04, 2021	SELL	$80.55 - $106.05 $688,702 - $906,727	-8,550 Closed	0 $0
Q3 2020 Oct 23, 2020	SELL	$89.56 - $126.72 $9,851 - $13,939	-110 Reduced 1.27%	8,550 $815,000
Q2 2020 Aug 03, 2020	SELL	$68.28 - $123.65 $22,464 - $40,680	-329 Reduced 3.66%	8,660 $969,000
Q4 2019 Feb 10, 2020	SELL	$96.94 - $113.59 $20,745 - $24,308	-214 Reduced 2.33%	8,989 $937,000
Q3 2019 Oct 23, 2019	SELL	$86.25 - $120.16 $1,811 - $2,523	-21 Reduced 0.23%	9,203 $916,000

Q2 2019 Jul 18, 2019	SELL	$107.38 - $129.34 $2,899 - $3,492	-27 Reduced 0.29%	9,224 $1.05 Million
Q1 2019 Apr 22, 2019	BUY	$105.93 - $142.47 $979,958 - $1.32 Million	9,251 New	9,251 $1.16 Million
Q4 2018 Jan 10, 2019	SELL	$128.36 - $272.13 $990,810 - $2.1 Million	-7,719 Closed	0 $0
Q4 2018 Jan 10, 2019	BUY	$128.36 - $272.13 $990,810 - $2.1 Million	7,719 New	7,719 $1.05 Million

234

16.5M

77.9K

25K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.43B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Foundry Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Foundry Partners, LLC with notifications on news.